Last reviewed · How we verify
irinotecan plus lobaplatin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
irinotecan plus lobaplatin (irinotecan plus lobaplatin) — ShengFa Su.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| irinotecan plus lobaplatin TARGET | irinotecan plus lobaplatin | ShengFa Su | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- irinotecan plus lobaplatin CI watch — RSS
- irinotecan plus lobaplatin CI watch — Atom
- irinotecan plus lobaplatin CI watch — JSON
- irinotecan plus lobaplatin alone — RSS
Cite this brief
Drug Landscape (2026). irinotecan plus lobaplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-plus-lobaplatin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab